Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Syndax price target lowered to $18 from $23 at Scotiabank
Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...
GlobalData on MSN1d
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients ...
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer
Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...
FierceBiotech2d
Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22%
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...
Syndax falls after mid-stage data for leukemia drug
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...
ETF Daily News7d
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have been given a consensus recommendation of ...
bovnews7d
What’s Causing Syndax Pharmaceuticals Inc (SNDX) Stock’s -4.60% Drop Over the Last Six Months?
On Wednesday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $21.35 which represents a slight increase of $1.66 or 8.43% from the prior close of $19.69. The stock ...